Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Ibezapolstat is a DNA polymerase IIIC inhibitor that is currently undergoing Phase II clinical development for the treatment of C. difficile infection (CDI). This drug has a unique mechanism of action that specifically targets low G+C content Gram-positive bacteria, with a primary focus on Firmicutes, including C. difficile. Results from Phase I trials involving healthy volunteers showed a favorable microbiome profile, which suggests that the drug may have an anti-recurrence effect (1)
XXX - Ibezapolstat & Clostridioides difficile infection (CDI) (initial) is a clinical phase IIa treatment trial studying Ibezapolstat (450 mg twice daily for 10 days) in 10 patients (enrolled) with mild-moderate [Clostridioides difficile infectio…